Crizotinib
Crizonix contains the cancer drug Crizotinib, a kinase inhibitor indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is FDA-approved as a therapy for both ALK positive and ROS1-positive metastatic NSCLC. It is the only FDA approved drug for ROS 1 positive NSCLC.
Dosage and Administration
Each pack of Crizonix contains 28 x 250mg capsules.
Your doctor will prescribe you a specific dose. Your doctor should also advise how often to take Crizotinib, when to take Crizotinib and how long to take Crizotinib for.
Precautions
Crizonix can be used by:
- adults with ALK-positive advanced NSCLC (non-small cell lung cancer)
- adults with previously treated ALK-positive advanced NSCLC & ROS1 (+) NSCLC
Interaction
CYP3A Inhibitors: Concurrent use of Crizonix avoided with strong CYP3A inhibitors including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole
CYP3A Inducers: Use of Crizotinib should avoid with strong CYP3A inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John’s Wort
The most common adverse reactions (≥25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.
Reviews
There are no reviews yet.
Related products
Uncategorized
Uncategorized
Uncategorized
Uncategorized
Uncategorized
Uncategorized
Uncategorized
Uncategorized
Be the first to review “Crizonix (Crizotinib)”